A form of ketamine- Esketamine- has been approved by the FDA for treatment-resistant depression in adults. Members of the FDA panel referred to the new medicine as a possible “game changer” for patients suffering with severe depression. Esketamine is in the form of a nasal spray and is administered in, and stored at, the doctor’s office. It is intended and approved to be used along with an oral antidepressant. Several clinical trials demonstrated its safety and efficacy, showing that the medicine improves depression severity as well as lengthens the time to depression relapse. The medicine is named Spravato and we are investigating how our patients can benefit. For Princeton treatment sites select this link.